Home > News > 6th Annual Biopharma Development and Production Week China 2020
Industry Updates New Products Supplier News Upcoming Events business web

6th Annual Biopharma Development and Production Week China 2020

Hits:230   Date: 6/16/2020
6th Annual Biopharma Development and Production Week China 2020

China’s biologics market continues to aggressively expand and achieve greater heights – regulatory reforms, new investments into the biopharma sector, more international partnerships coming into place and local biopharmas looking to go global. Product innovation and investment opportunities are in abundance as China leads the way as the 2nd largest biologics market in the world.
With numerous shifts on the horizon, the Chinese industry approaches a tipping point as companies reevaluate current trends and strategies to achieve commercial excellence. The 6th iteration of BDP Week will address the 2020 investment climate, technological advancements, industry case studies, and partnerships and expansion opportunities across key value chains.
With improved networking windows and elevated exhibition platforms, join us as the industry convenes at this highly anticipated annual gathering of biopharma leaders.
Conference Day 1 | 3 November 2020
China’s Big Leap Towards BioPharma 2030 – Innovation, Industrialization, InternationalizationDr. Song Ru Lin, Executive President, China Pharmaceutical Innovation and Research Development Association (PhIRDA), ChinaKEYNOTE ADDRESS
China’s Biological Facilities for the Future – WuXi’s Story on Technology and InnovationDr. Chris Chen, Chief Executive Officer, WuXi Biologics, ChinaManufacturers’ Panel:
New Therapies, New Tech and New Investments
* New frontiers in drug development
* What is the gap in quality and investment?
* Embracing new tech and start-ups to drive progress
* New therapeutics manufacturing, commercialisation and global access
* Biomanufacturing 4.0 – Where are we at?
* DAL’s GAMP and licensing laws – How is it affecting our business and what we can expect?
* The GQCE framework – quality consistency and better pricing
Conference Day 2 | 4 November 2020
China’s Biopharma Capital Markets – Future Funds and Innovative Financing Fu Wei, Chief Executive Officer, CBC Group, China Venture Capitals Roundtable: Show Me the Drug 
* Investment landscape of Chinese biopharma market
* Evaluating drug pipelines and development prospects
* Mergers, expansion and JVs – Where do we see transactions picking up?
* Financing new plants, new therapeutics, product launch and scaling-up operations – How do we review?
* Manufacturing 4.0 – How do VCs and banks play a part in modernising the value chain?
Contact us:
Eva Yeo
Direct line: +65 6508 2423
Conference website: https://www.biopharmaproduction.com